Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of CEPSP chemotherapy plus radiotherapy for newly diagnosed stage IV extranodal NK/T-cell lymphoma, nasal type
ChiCTR-OOC-15006656Phase 2Completed
- Sponsor
- Department of Oral and Maxillofacial Surgery, Stomatological Hospital of Xi'an Jiaotong University
- Start
- Oct 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin, etoposide, pingyangmycin, semustine and prednisone in Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL), sponsored by Department of Oral and Maxillofacial Surgery, Stomatological Hospital of Xi'an Jiaotong University. Primary endpoints: progression-free survival rate, overall survival rate and 2 more. Started Oct 2014; status: completed.
02
Drugs
cisplatinetoposidepingyangmycinsemustineprednisone
03
Conditions
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)
Beyond the preview
Go deeper on ChiCTR-OOC-15006656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OOC-15006656.